Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | CAT | P04040 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HNF4A | P41235 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27268876 | 0.86 | — | — | |
| SCHEMBL21503796 | 0.82 | MAPT (0.33) | CYP2C9CDC25BALDH1A1KDM4EBRD4 | |
| SCHEMBL27268429 | 0.78 | CAT (0.37) | CAT | |
| SCHEMBL21497088 | 0.78 | CAT (0.54) | CAT | |
| SCHEMBL21497092 | 0.78 | CAT (0.54) | CAT | |
| SCHEMBL27268433 | 0.78 | CAT (0.37) | CAT | |
| SCHEMBL21497090 | 0.78 | CAT (0.54) | CAT | |
| SCHEMBL27268431 | 0.78 | CAT (0.37) | CAT | |
| SCHEMBL27270450 | 0.78 | — | — | |
| SCHEMBL18089736 | 0.77 | CYP2C9 (0.33) | CYP2C9CDC25BALDH1A1ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307422-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3781576-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20210361682-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3781576-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019204419-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204419-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307422-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | CYP2C9 1924/4885CDC25B 2353/4885MMP2 2106/4885 |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BCL6, BTD | CYP2C9 2114/4885CDC25B 2227/4885MMP2 1984/4885 |
| US-20210361682-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | CYP2C9 2114/4885CDC25B 2227/4885MMP2 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.